Download the full report (112 p.) - KCE
Download the full report (112 p.) - KCE
Download the full report (112 p.) - KCE
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
52 Interventions in Alzheimer’s Disease <strong>KCE</strong> Reports 111<br />
5.1.4.2 Primary <strong>full</strong> economic evaluations<br />
References<br />
Table 11 lists <strong>the</strong> 17 primary economic evaluations published after 2004 and retained.<br />
Table 11: Primary economic evaluations of Alzheimer’s disease and<br />
dementia treatments (search date: 2004 – August 2008)<br />
Cholinesterase Inhibitors (n = 2)<br />
Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of<br />
donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess.<br />
2006;10(1):iii-iv. 72<br />
Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling <strong>the</strong> cost effectiveness of<br />
cholinesterase inhibitors in <strong>the</strong> management of mild to moderately severe Alzheimer's disease.<br />
Pharmacoeconomics. 2005;23(12):1271-82. 98<br />
Donepezil (n = 4)<br />
Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in<br />
Taiwan. International Journal of Geriatric Psychiatry. 2008;23(1):73-8. 96<br />
Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of<br />
donepezil for <strong>the</strong> treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci.<br />
2007;257(6):330-6. 102<br />
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of donepezil in<br />
moderate to severe Alzheimer disease. Neurology. 2004;63(4):644-50. 94<br />
Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, Seux ML, et al. Donepezil for <strong>the</strong> treatment of<br />
mild to moderate Alzheimer's disease in France: <strong>the</strong> economic implications. Dementia & Geriatric<br />
Cognitive Disorders. 2004;17(1-2):5-13. 93<br />
Galantamine (n = 1)<br />
Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Assessing <strong>the</strong> health and<br />
economic impact of galantamine treatment in patients with Alzheimer's disease in <strong>the</strong> health care<br />
systems of different countries. Drugs & Aging. 2004;21(10):677-86. 92<br />
Memantine (n = 6)<br />
Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard<br />
care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519-26. 97<br />
Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, et al. Cost-effectiveness of<br />
memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res<br />
Opin. 2007;23(5):1187-97. 103<br />
Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in<br />
community-based Alzheimer's disease patients: An adaptation in Spain. Eur J Health Econ.<br />
2006;7(2):137-44. 91<br />
Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.<br />
Am J Geriatr Pharmaco<strong>the</strong>r. 2005;3(2):77-86. 100<br />
Jones RW, McCrone P, Guilhaume C. Cost-effectiveness of memantine in Alzheimer's disease: an<br />
analysis based on a probabilistic Markov model from a UK perspective. Drugs & Aging.<br />
2004;21(9):607-20. 99<br />
Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to<br />
severe Alzheimer's disease: A Markov model in Finland. Clinical Drug Investigation. 2004;24(7):373-<br />
84. 95